Back to results
US 12,466,896 B2Granted
Anti-CD3 antibodies and methods of use
AssigneeGenentech, Inc.
InventorsXiaocheng Chen, Mark S. Dennis, Allen J. Ebens, Jr., Robert F. Kelley, Mary A. Mathieu, Liping L. Sun
Life of this patent
Estimating the term…
Abstract
The invention provides anti-cluster of differentiation 3 (CD3) antibodies and methods of using the same.
Claims31
A method of producing a bispecific antibody that binds to CD20 and CD3,
- the method comprising culturing host cells expressing one or more isolated nucleic acids, the one or more isolated nucleic acids encoding the bispecific antibody, wherein the bispecific antibody comprises:
- (a) an anti-CD20 arm comprising a first binding domain, the first binding domain comprising:
- a hypervariable region (HVR)-H1 comprising the amino acid sequence of SEQ ID NO:
- 157,
- an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 158,
- an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 159,
- an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 160,
- an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 161, and
- an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 162;
- and
- (b) an anti-CD3 arm comprising a second binding domain, the second binding domain comprising:
- an HVR-H1 comprising the amino acid sequence of SEQ ID NO:
- 1,
- an HVR-H2 comprising the amino acid sequence of SEQ ID NO:
- 2,
- an HVR-H3 comprising the amino acid sequence of SEQ ID NO:
- 3,
- an HVR-L1 comprising the amino acid sequence of SEQ ID NO:
- 4,
- an HVR-L2 comprising the amino acid sequence of SEQ ID NO:
- 5, and
- an HVR-L3 comprising the amino acid sequence of SEQ ID NO:
- 6.
25 more elements
A method of producing a bispecific antibody that binds to CD20 and CD3,
- the method comprising culturing host cells expressing one or more isolated nucleic acids, the one or more isolated nucleic acids encoding the bispecific antibody,
- wherein the bispecific antibody comprises an anti-CD20 arm comprising a first binding domain comprising (a) a VH domain comprising the amino acid sequence of SEQ ID NO:
- 266 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO:
- 267, and an anti-CD3 arm comprising a second binding domain comprising (a) a VH domain comprising the amino acid sequence of SEQ ID NO:
- 184 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO:
- 185.
3 more elements
A method of producing a bispecific antibody that binds to CD20 and CD3,
- the method comprising culturing CHO cells expressing one or more isolated nucleic acids, the one or more isolated nucleic acids encoding the bispecific antibody,
- wherein the bispecific antibody comprises an anti-CD20 arm comprising a first binding domain comprising (a) a VH domain comprising the amino acid sequence of SEQ ID NO:
- 266 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO:
- 267, and an anti-CD3 arm comprising a second binding domain comprising (a) a VH domain comprising the amino acid sequence of SEQ ID NO:
- 184 and (b) a VL domain comprising the amino acid sequence of SEQ ID NO:
- 185, wherein (a) the anti-CD3 arm comprises T366S, L368A, Y407V, and N297G substitution mutations and (b) the anti-CD20 arm comprises T366W and N297G substitution mutations (EU numbering).
3 more elements
Dependencies are inferred from the claim text.